FOXO3 and COVID-19: Since FOXO3 shows the same expression trend as ATP2B1, with reduced expression levels in the lung of COVID-19 patients (ATP2B1, Fig. EV1G; FOXO3, Fig. EV3E) we hypothesized that FOXO3 is a candidate transcription factor that would be able to control ATP2B1 expression.